Uniting Disciplines to Develop Therapeutics: Targeted mRNA Lipid Nanoparticles Reprogram the Immune System In Vivo to Treat Heart Disease.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and commentary without human clinical data (CEBM Level 5).
PubMed 35446147 · doi:10.1089/dna.2022.0171
What was done
The authors describe a strategy to deliver modified mRNA via targeted lipid nanoparticles to T cells in vivo, producing transient anti-activated fibroblast immune cells to reduce cardiac fibrosis in a murine model.
What was found
The engineered cells remained active for only a few days but were reported to significantly improve cardiac function in mice with cardiac fibrosis. No quantitative values, sample sizes, or effect estimates are reported in the abstract.
Why it matters
Generating transient CAR-like T cells directly in vivo provides a potential route for titratable, lower-cost cell therapies for fibrotic diseases without causing permanent fibroblast depletion.
Limits
This is a narrative summary of preclinical animal research with no human clinical data. The abstract provides no sample sizes, numerical outcomes, statistical metrics, or long-term safety data.
Cited by
- supports Researchers at a University of Pennsylvania spinout developed targeted lipid nanoparticles that bind T cells in the bloodstream to deliver mRNA encoding CARs and generate CAR T cells in vivo.